Focus: Genesis Therapeutics is an AI-driven drug discovery biotech focused on oncology, neurology, cardiovascular, women's health, and immunology. The company operates at Series B stage from Burlingame, CA with a lean 11-person hiring footprint.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Best for AI/computational scientists and data engineers seeking early-stage equity exposure and platform-building opportunity; higher risk for those seeking revenue stability or clear clinical validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Genesis Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Genesis Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Application of modelling of cell monolayer permeation data to generate input parameters compatible with in vitro-in vivo translation of blood-brain-barrier disposition of drugs.
Comparing massively-multitask regression algorithms for drug discovery.
Showing 5 of 10 publications